https://www.credenceresearch.com/news/marvell-acquire-lumentum-115-billion-all-stock-ai-connectivity Credence Research en 2026-11-02T13:00:29.000Z Marvell to Acquire Lumentum in $115 Billion All-Stock Deal to Build AI Connectivity Supplier https://www.credenceresearch.com/news/fresenius-wuxi-biologics-exclusive-agreement-37-biosimilar-candidates Credence Research en 2026-11-02T11:01:14.000Z Fresenius Signs WuXi Biologics Deal for Up to 37 Biosimilar Candidates Over Next Decade https://www.credenceresearch.com/news/us-steel-breaks-ground-1-9-billion-direct-reduced-iron-plant-osceola-arkansas Credence Research en 2026-11-02T09:00:55.000Z U.S. Steel Breaks Ground on $1.9 Billion Direct Reduced Iron Plant in Osceola, Arkansas https://www.credenceresearch.com/news/foxconn-hon-hai-tech-day-2026-nvidia-dsx-pod-openai-collaboration Credence Research en 2026-11-02T07:00:10.000Z Foxconn shows factory-built Nvidia AI pods at Hon Hai Tech Day, points to new OpenAI work https://www.credenceresearch.com/news/tata-motors-takes-control-iveco-89-42-percent-stake-tender-offer-settlement Credence Research en 2026-11-02T04:55:45.000Z Tata Motors Takes Control of Iveco With 89.42% Stake as Tender Offer Settles https://www.credenceresearch.com/news/valero-acquire-lyondellbasell-houston-refinery-restart-165000-bpd-2027 Credence Research en 2026-11-02T03:10:37.000Z Valero to Buy LyondellBasell's Idled Houston Refinery, Restart 165,000 b/d by End-2027 https://www.credenceresearch.com/news/fda-approves-inovio-voceryq-first-plasmid-dna-immunotherapy-recurrent-respiratory-papillomatosis Credence Research en 2026-11-02T01:02:37.000Z FDA Approves Inovio's Voceryq, First Plasmid DNA Immunotherapy, for Recurrent Respiratory Papillomatosis